Affiliations: [a] Department of Laboratory Medicine, People’s Hospital of Weifang, Weifang 266001, Shandong, China | [b] Department of Internal Medicine, People’s Hospital of Rizhao, Rizhao 276800, Shandong, China | [c] Department of Internal Medicine, People’s Hospital of Zhangqiu, Zhangqiu 250200, Shandong, China | [d] Department of Imaging, People’s Hospital of Zhangqiu, Zhangqiu 250200, Shandong, China | [e] Department of Oncological Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao 266071, Shandong, China | [f] Department of Emergency Surgery, Qingdao Hiser Medical Center, Qingdao 266001, Shandong, China
Correspondence:
[*]
Corresponding author: Linghua Zhang, Department of Emergency Surgery, Qingdao Hiser Medical Center, No. 4 Renmin Road, Qingdao 266001, Shandong, China. Tel.: +86 0532 83777856; Fax: +86 0532 83777888; E-mail: [email protected].
Abstract: Thyroid carcinoma is one of the most frequent malignant tumors of the endocrine system, which accounts for nearly 1% population in newly diagnosed carcinoma worldwide and the incidence has an increasing tendency in recent years. To explore whether miR-135a-5p could affect the proliferation, invasion and migration of thyroid carcinoma cells by targeting VCAN. The expression levels of miR-135a-5p and VCAN were detected in human thyroid carcinoma tissues and cells, para-carcinoma tissues, as well as human normal thyroid cells using RT-qPCR and Western blot. In addition, dual-luciferase reporter gene assay, MTT assay, colony formation assay, wound healing assay, Transwell assay, flow cytometry analysis and in vivo tumorigenesis assay were also conducted. The results demonstrated that miR-135a-5p was down-regulated while VCAN was up-regulated both in thyroid carcinoma tissues and cells. Furthermore, the up-regulation of miR-135a-5p inhibited cell proliferation, invasion and migration of thyroid carcinoma. Dual-luciferase reporter gene assay provided evidence indicating that miR-135a-5p targeted VCAN in thyroid carcinoma. MiR-135a-5p could inhibit cell proliferation, invasion and migration of thyroid carcinoma by targeting VCAN. MiR-135a-5p and VCAN might emerge as a target for the treatment of thyroid carcinoma.
